<SEC-DOCUMENT>0001213900-25-103261-index.html : 20251029 <SEC-HEADER>0001213900-25-103261.hdr.sgml : 20251029 <ACCEPTANCE-DATETIME>20251029080507 ACCESSION NUMBER: 0001213900-25-103261 CONFORMED SUBMISSION TYPE: SCHEDULE 13D/A PUBLIC DOCUMENT COUNT: 10 FILED AS OF DATE: 20251029 DATE AS OF CHANGE: 20251029 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LakeShore Biopharma Co., Ltd. CENTRAL INDEX KEY: 0001946399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SCHEDULE 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-94412 FILM NUMBER: 251426913 BUSINESS ADDRESS: STREET 1: BUILDING NO. 2, 38 YONGDA ROAD STREET 2: DAXING BIOMEDICAL INDUSTRY PARK CITY: DAXING DISTRICT, BEIJING STATE: F4 ZIP: 102629 BUSINESS PHONE: 17327133678 MAIL ADDRESS: STREET 1: BUILDING NO. 2, 38 YONGDA ROAD STREET 2: DAXING BIOMEDICAL INDUSTRY PARK CITY: DAXING DISTRICT, BEIJING STATE: F4 ZIP: 102629 FORMER COMPANY: FORMER CONFORMED NAME: YS Biopharma Co., Ltd. DATE OF NAME CHANGE: 20230310 FORMER COMPANY: FORMER CONFORMED NAME: YishengBio Co., Ltd DATE OF NAME CHANGE: 20220912 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Crystal Peak Investment Inc. CENTRAL INDEX KEY: 0002078050 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SCHEDULE 13D/A BUSINESS ADDRESS: STREET 1: 3877 EL CAMINO REAL, STE 201 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 86 13335711066 MAIL ADDRESS: STREET 1: 3877 EL CAMINO REAL, STE 201 CITY: PALO ALTO STATE: CA ZIP: 94306 </SEC-HEADER> <DOCUMENT> <TYPE>SCHEDULE 13D/A <SEQUENCE>1 <FILENAME>primary_doc.xml <TEXT> Document 1 - file: primary_doc.html
Document 1 - RAW XML: primary_doc.xml
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>ea026254001ex99-1_crystal.htm <DESCRIPTION>EXECUTIVE OFFICERS AND DIRECTORS <TEXT> Document 2 - file: ea026254001ex99-1_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>ea026254001ex99-2_crystal.htm <DESCRIPTION>JOINT FILING AGREEMENT DATED OCTOBER 29, 2025 BY AND AMONG THE REPORTING PERSONS <TEXT> Document 3 - file: ea026254001ex99-2_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>4 <FILENAME>ea026254001ex99-3_crystal.htm <DESCRIPTION>PROPOSAL DATED AUGUST 18, 2025 FROM OCEANPINE TO THE BOARD OF DIRECTORS OF THE ISSUER <TEXT> Document 4 - file: ea026254001ex99-3_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.4 <SEQUENCE>5 <FILENAME>ea026254001ex99-4_crystal.htm <DESCRIPTION>CONSORTIUM AGREEMENT DATED AUGUST 26, 2025 BY AND AMONG OCEANPINE INVESTMENT, OCEANPINE CAPITAL, AND CRYSTAL INVESTMENT <TEXT> Document 5 - file: ea026254001ex99-4_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.5 <SEQUENCE>6 <FILENAME>ea026254001ex99-5_crystal.htm <DESCRIPTION>REVISED PROPOSAL DATED AUGUST 26, 2025 FROM OCEANPINE AND CRYSTAL INVESTMENT TO THE BOARD OF DIRECTORS OF THE ISSUER <TEXT> Document 6 - file: ea026254001ex99-5_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.6 <SEQUENCE>7 <FILENAME>ea026254001ex99-6_crystal.htm <DESCRIPTION>DEED OF ADHERENCE BY ADJUVANT FUND AND ADJUVANT FUND DE DATED OCTOBER 5, 2025 <TEXT> Document 7 - file: ea026254001ex99-6_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.7 <SEQUENCE>8 <FILENAME>ea026254001ex99-7_crystal.htm <DESCRIPTION>DEED OF ADHERENCE BY SUPERSTRING CAPITAL DATED OCTOBER 27, 2025 <TEXT> Document 8 - file: ea026254001ex99-7_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.8 <SEQUENCE>9 <FILENAME>ea026254001ex99-8_crystal.htm <DESCRIPTION>DEED OF ADHERENCE BY MSA GROWTH DATED OCTOBER 27, 2025 <TEXT> Document 9 - file: ea026254001ex99-8_crystal.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.9 <SEQUENCE>10 <FILENAME>ea026254001ex99-9_crystal.htm <DESCRIPTION>DEED OF ADHERENCE BY EPIPHRON CAPITAL DATED OCTOBER 27, 2025 <TEXT> Document 10 - file: ea026254001ex99-9_crystal.htm
</DOCUMENT> </SEC-DOCUMENT>